Home Pipeline

Overview

MacroGenics has a diverse portfolio of proprietary product candidates with several clinical trials currently underway or planned for the near future. Set forth below is the company’s development pipeline of product candidates for which we have retained commercialization or other important rights in the U.S. or more broadly.

 

Program (Target) Potential Indication(s) First-in-Human (Phase 1) Proof-of-Concept (Phase 2) Pivotal Major Market Rights
Margetuximab
(HER2)
HER2+ Breast
placeholder
placeholder
placeholder
Greater China
HER2+ Gastric/GEJ (+retifanlimab/MGD013)
placeholder
placeholder
Flotetuzumab
(CD123 x CD3)
AML
placeholder
placeholder
placeholder
Retifanlimab
(PD-1)
Solid Tumors
placeholder
placeholder
placeholder
(b)

Enoblituzumab
(B7–H3)
SCCHN (+MGA012/MGD013)
placeholder
placeholder
Greater China
Tebotelimab
(PD-1 x LAG-3)
Solid Tumors & Heme Malignancies
placeholder
placeholder
Greater China
MGD019
(PD-1 x CTLA-4)
Solid Tumors
placeholder
MGC018
(B7-H3)(a)
Solid Tumors
placeholder

Oncology
HER2+ Breast
Phase 1 Phase 2 Pivotal
placeholder
placeholder
placeholder
HER2+ Gastric/GEJ (+retifanlimab/MGD013)
Phase 1 Phase 2 Pivotal
placeholder
placeholder
Major Market Rights:

Greater China
Flotetuzumab (CD123 x CD3)
AML
Phase 1 Phase 2 Pivotal
placeholder
placeholder
placeholder
Major Market Rights:
Solid Tumors
Phase 1 Phase 2 Pivotal
placeholder
placeholder
placeholder
Major Market Rights:
Solid Tumors (+anti-PD-1)
Phase 1 Phase 2 Pivotal
placeholder
placeholder
Major Market Rights

Greater China
tebotelimab (PD-1 x LAG-3)
Solid Tumors/Heme Mal.
Phase 1 Phase 2 Pivotal
placeholder
placeholder
Major Market Rights

Greater China
MGC018 (B7-H3)(a)
Solid Tumors
Phase 1 Phase 2 Pivotal
placeholder
Major Market Rights

MGD019 (PD-1 x CTLA-4)
Solid Tumors
Phase 1 Phase 2 Pivotal
placeholder
Major Market Rights
“MGD” = DART “MGA” = Antibody“MGC” = ADC
(a) MGC018 is an antibody-drug conjugate (ADC) based on a duocarmycin payload with cleavable peptide linker that was licensed from Byondis (formerly Synthon Biopharmaceuticals).
(b) MacroGenics retains rights to develop its pipeline assets in combination w/retifanlimab (MGA012) and to manufacture a portion of global clinical and commercial supply needs of retifanlimab.
All Company product candidates described or mentioned herein are investigational and have not yet been approved for marketing by any regulatory authority.

Please note – you will leave a website owned by MacroGenics, Inc.

MacroGenics is not responsible for any content on the third party website.

Ok Close